Catherine T.
- Country
- France
- Department
- Service d’oncohématologie
Research Overview
- Evaluation of Venetoclax Combined With Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Untreated BCL-2 IHC-Positive DLBCL Patients
- Safety Evaluation of REGN5837 Combined with Odronextamab in Patients with Aggressive B-cell Non-Hodgkin Lymphomas
- Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Data & Insights
Has run more than one trial at 337 of 519 partner sites.
Specializations
B-Cell Lymphomas
Specializes in investigating novel therapeutic approaches for diffuse large B-cell lymphoma and follicular lymphoma, with particular focus on combination therapies and targeted treatments.
- Advanced B-cell lymphoma treatments
- Bispecific antibody therapies
- CAR T-cell therapy applications
Extensive experience in evaluating emerging treatments for aggressive and indolent B-cell lymphomas.
T-Cell Lymphomas
Conducts research in peripheral T-cell lymphoma treatment modalities, focusing on innovative therapeutic combinations and novel drug development.
- Targeted therapy approaches
- Immunotherapy combinations
- Novel drug evaluation
Specialized expertise in treating refractory and relapsed T-cell lymphoma cases.
Chronic Lymphocytic Conditions
Focuses on developing treatments for chronic lymphocytic leukemia and related disorders, investigating novel therapeutic combinations.
- Targeted molecular therapies
- Immunotherapy approaches
- Treatment resistance strategies
Particular interest in developing treatments for high-risk and refractory disease states.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.